31,145 Shares in Becton, Dickinson and Company $BDX Acquired by First Nebraska Trust Co

First Nebraska Trust Co purchased a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor purchased 31,145 shares of the medical instruments supplier’s stock, valued at approximately $5,575,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. TD Waterhouse Canada Inc. lifted its position in Becton, Dickinson and Company by 17.1% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 96,211 shares of the medical instruments supplier’s stock worth $14,715,000 after acquiring an additional 14,077 shares during the last quarter. Northside Capital Management LLC grew its position in shares of Becton, Dickinson and Company by 18.3% in the second quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier’s stock valued at $9,280,000 after purchasing an additional 9,494 shares during the last quarter. NewEdge Advisors LLC grew its position in shares of Becton, Dickinson and Company by 35.0% in the first quarter. NewEdge Advisors LLC now owns 44,032 shares of the medical instruments supplier’s stock valued at $6,923,000 after purchasing an additional 11,414 shares during the last quarter. Beverly Hills Private Wealth LLC bought a new position in shares of Becton, Dickinson and Company in the second quarter worth about $3,353,000. Finally, Wealthfront Advisers LLC bought a new position in shares of Becton, Dickinson and Company in the second quarter worth about $2,567,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on BDX. Royal Bank Of Canada boosted their price objective on Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a research report on Thursday, August 13th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $210.00 target price on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. Wolfe Research assumed coverage on Becton, Dickinson and Company in a research report on Tuesday, October 20th. They issued an “outperform” rating on the stock. Bank of America upped their price target on Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Monday, August 31st. Finally, UBS Group began coverage on Becton, Dickinson and Company in a report on Tuesday, July 28th. They set a “buy” rating and a $190.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Becton, Dickinson and Company has a consensus rating of “Moderate Buy” and a consensus target price of $185.07.

Becton, Dickinson and Company Stock Down 0.4%

Shares of BDX opened at $197.88 on Wednesday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The company has a 50-day simple moving average of $186.86 and a 200-day simple moving average of $170.20. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $200.47. The firm has a market capitalization of $54.52 billion, a P/E ratio of 59.60, a P/E/G ratio of 13.39 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The business had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same period last year, the business earned $3.68 earnings per share. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities research analysts expect that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael Feld sold 165 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the sale, the executive vice president owned 19,720 shares in the company, valued at approximately $3,717,022.80. This trade represents a 0.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the sale, the executive vice president directly owned 14,856 shares in the company, valued at $2,686,559.04. The trade was a 14.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 6,907 shares of company stock valued at $1,269,128 in the last quarter. Corporate insiders own 0.40% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.